可溶性细胞粘附分子-1在糖尿病肾病中的检测

目的　检测糖尿病肾病 (DN)患者体内可溶性细胞粘附分子 - 1(sICAM - 1)含量及其与糖尿病微血管病变的体系。方法　采用ELISA双抗夹心法对 4 8例Ⅱ型糖尿病肾病 (G1组 )患者尿液、血液及外周血单个核细胞PHA体外刺激培养上清 (CPBMCs)中的sICAM - 1含量进行检测 ,并与 4 6例肾功能正常的Ⅱ型糖尿病(G2组 )及 4 8例健康人 (G3组 )比较。结果　G1组尿液和血浆中的SICAM - 1水平明显升高 ,其尿液中含量(45 0 18± 81 2 5 )fg·L- 1与G2组 (2 31 37± 18 5 7)fg·L- 1和G3组 (2 0 4 5 9± 2 7 36 )fg·L- 1比较 ,P均 <0 0 1。血浆中含量 (2 87 4 5± 6 1 0 6 )fg·L- 1与G2组 (15 8 91± 11 0 3)fg·L- 1和G3组 (137 2 5± 6 2 2 )fg·L- 1比较 ,分别为P <0 0 5和P <0 0 1。G2组与G3组之间比较 ,尿液及血浆中含量均无明显差异 (P >0 0 5 ) ,G1组患者CPBMCs中的sICAM - 1含量与G2 ,G3组之间P >0 0 5。结论　尿液和血浆中sICAM - 1含量检测可能作为判断DN病情活动的一项有意义指标。

Detection of SICAM-1 in Diabetic Nephrosis

Objective To test SICAM-1 in the patients with diabetic nephrosis and the relationship between SICAM and microangiopathy in diabetes. Methods Test SICAM in blood and in CPBMCs of 48 NIDDM patients(Group 1) with ELISA, and compare them with those of 46 NIDDM patients with normal kidney functions(Group 2) and 48 healthy cases(Group 3). Results The SICAM level in urine and plasma of G1 is higher than those of G2 and G3, but SICAM level in CPBMCs is no higher than those of G2 and G3. Conclusion Test of SICAM in urine and plasma can act as an reasonable index to judge the progress of diabetic nephrosis.